RecruitingNot ApplicableNCT07128030

Moderate-Intensity Exercise and Pain Sensitization in Breast Cancer Survivors: A Case-Based Study


Sponsor

Universidad Rey Juan Carlos

Enrollment

10 participants

Start Date

Aug 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study was to evaluate the feasibility, safety, and acceptability of a supervised, combined moderate-intensity aerobic and resistance training program designed to reduce pain sensitization in BCS with persistent pain. Secondary objectives included assessing changes in pain intensity, somatosensory sensitivity, and temporal summation, while tertiary objectives focused on improvements in quality of life and functional capacity.


Eligibility

Sex: FEMALE

Inclusion Criteria3

  • Adult women diagnosed with stage I-III breast cancer
  • Completion of active treatment (surgery, chemotherapy, and/or radiotherapy) at least 6 months prior to enrollment
  • Presence of persistent pain or altered sensation in the upper quadrant of the affected limb related to oncologic treatment

Exclusion Criteria7

  • Bilateral breast cancer
  • Locoregional recurrence
  • Other malignancies
  • Pre-existing pain not related to cancer treatment
  • Neurological or cognitive disorders
  • Non-Spanish speakers
  • Contraindications to moderate-intensity physical activity

Interventions

OTHERExercise

The experimental group completed a five-week supervised program combining moderate-intensity aerobic and resistance training (150 min/week). Intensity was monitored using the Borg and OMNI-Res scales after familiarization sessions. Adherence was encouraged through reminders, motivational messages, and follow-ups. Unlike prior studies, this intervention focused specifically on neurophysiological pain modulation. Sessions included step-based aerobic exercises and resistance training with elastic bands under safety protocols.


Locations(1)

Universidad Rey Juan Carlos

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07128030


Related Trials